Surrozen (SRZN) Stock Price, News & Analysis

Company Overview

Surrozen, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis. Surrozen’s pipeline spans both preclinical and clinical stages and includes programs addressing ocular surface disease, gastrointestinal disorders and solid tumors—indications characterized by impaired tissue healing or dysregulated Wnt activity.

To advance its pipeline, Surrozen has entered into strategic collaborations and research agreements with academic institutions and biopharmaceutical partners. These alliances are aimed at validating novel Wnt targets, enhancing antibody design and accelerating the translation of lead candidates into clinical development. The company is actively preparing multiple investigational new drug applications and expects to initiate additional clinical trials in the near term.

Surrozen is led by President and Chief Executive Officer Laura Shawver, PhD, supported by a management team with deep expertise in antibody engineering, developmental biology and translational medicine. The company’s research and development operations are based in the San Francisco Bay Area, where it maintains dedicated laboratory and manufacturing facilities to support its growing pipeline.

Key Stats

• Today's Range: $13.28 to $13.77
• 50-Day Range: $9.03 to $13.77
• 52-Week Range: $5.90 to $18.17
• Volume: 6,729 shs
• Average Volume: 23,200 shs
• Market Capitalization: $115.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $38.50
• Consensus Rating: Hold

Surrozen Stock Analysis - MarketRank™

Surrozen scored higher than 36% of companies evaluated by MarketBeat, and ranked 733rd out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Surrozen has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Surrozen has a consensus price target of $38.50, representing about 186.2% upside from its current price of $13.45.

Amount of Analyst Coverage

Surrozen has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Surrozen are expected to decrease in the coming year, from ($8.49) to ($10.71) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Surrozen is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Surrozen is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

1.98% of the float of Surrozen has been sold short.

Short Interest Ratio / Days to Cover

Surrozen has a short interest ratio ("days to cover") of 6.2.

Change versus previous month

Short interest in Surrozen has recently increased by 8.92%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Surrozen does not currently pay a dividend.

Dividend Growth

Surrozen does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.98% of the float of Surrozen has been sold short.

Short Interest Ratio / Days to Cover

Surrozen has a short interest ratio ("days to cover") of 6.2.

Change versus previous month

Short interest in Surrozen has recently increased by 8.92%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Surrozen this week, compared to 1 article on an average week.

Search Interest

4 people have searched for SRZN on MarketBeat in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Surrozen insiders have not sold or bought any company stock.

Percentage Held by Insiders

45.18% of the stock of Surrozen is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

66.57% of the stock of Surrozen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SRZN Stock Analysis - Frequently Asked Questions

How have SRZN shares performed this year?

Surrozen's stock was trading at $14.35 at the beginning of 2025. Since then, SRZN stock has decreased by 6.3% and is now trading at $13.4520.

How were Surrozen's earnings last quarter?

Surrozen, Inc. (NASDAQ:SRZN) issued its quarterly earnings data on Friday, August, 8th. The company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.23) by $0.09. The company had revenue of $0.98 million for the quarter. Surrozen had a negative trailing twelve-month return on equity of 545.43% and a negative net margin of 274.42%.

When did Surrozen's stock split?

Shares of Surrozen reverse split on Thursday, December 14th 2023.The 1-15 reverse split was announced on Thursday, December 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Surrozen?

Shares of SRZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Surrozen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Surrozen investors own include ACADIA Pharmaceuticals (ACAD), Marvell Technology (MRVL), HubSpot (HUBS), Avidity Biosciences (RNA), Adverum Biotechnologies (ADVM), Alpha and Omega Semiconductor (AOSL) and

Company Calendar

• Last Earnings: 8/08/2025
• Today: 10/05/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SRZN
• CIK: 1824893
• Web: www.consonancehfw.com
• Phone: 650-489-9000
• Fax: N/A
• Employees: 80
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Surrozen: $38.50
• High Price Target: $45.00
• Low Price Target: $32.00
• Potential Upside/Downside: +186.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($14.42)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$63.56 million
• Net Margins: -274.42%
• Pretax Margin: -132.29%
• Return on Equity: -545.43%
• Return on Assets: -64.40%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 16.41
• Quick Ratio: 16.41

Sales & Book Value

• Annual Sales: $10.65 million
• Price / Sales: 10.82
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($6.55) per share
• Price / Book: -2.05

Miscellaneous

• Outstanding Shares: 8,570,000
• Free Float: 4,698,000
• Market Cap: $115.28 million
• Optionable: Not Optionable
• Beta: 0.63